SCHEMBL22235212

SCHEMBL22235212

Cn1c2c(cc(C(=O)O)c1=O)[C@H](C(C)(C)C)Cc1c-2cc(OC(F)F)c2ncccc12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ PDE4D Q08499 1/20 0.32
▸ DRD1 P21728 3/20 0.31
▸ KAT2B Q92831 1/20 0.31
▸ PTGER4 P35408 1/20 0.31
▸ KDM6B O15054 1/20 0.30
▸ KDM6A O15550 1/20 0.30
▸ TET3 O43151 1/20 0.30
▸ KDM4A O75164 1/20 0.30
▸ KDM4B O94953 1/20 0.30
▸ KDM5C P41229 1/20 0.30
▸ KDM4D Q6B0I6 1/20 0.30
▸ TET2 Q6N021 1/20 0.30
▸ ALKBH5 Q6P6C2 1/20 0.30
▸ TET1 Q8NFU7 1/20 0.30
▸ FTO Q9C0B1 1/20 0.30
▸ EGLN1 Q9GZT9 1/20 0.30
▸ KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728938 1.00 KDM4E (0.32) KDM4ENPC1RAB9APDE4DDRD1
SCHEMBL22235214 1.00 KDM4E (0.32) KDM4ENPC1RAB9APDE4DDRD1
SCHEMBL22235909 0.83 SYK (0.31) KDM4ENPC1RAB9APDE4D
SCHEMBL22235890 0.83 SYK (0.31) KDM4ENPC1RAB9APDE4D
SCHEMBL22235348 0.80 PDE4D (0.30) PDE4D
SCHEMBL22235351 0.80 PDE4D (0.30) PDE4D
SCHEMBL22235347 0.80 PDE4D (0.30) PDE4D
SCHEMBL22235658 0.80 PDE4D (0.35) KDM4ENPC1RAB9APDE4DKAT2B
SCHEMBL29728910 0.80 PDE4D (0.30) PDE4D
SCHEMBL22235664 0.76 PDE4D (0.32) KDM4EPDE4DKAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125771-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2022-04-28 — — US disclosed
EP-3911653-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2021-11-24 — — EP disclosed
WO-2020150366-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125771-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, HDGF KDM4E 1195/4885NPC1 616/4885RAB9A 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback